Healthcare Global Enterprises Ltd

- The company announced a Rights Issue, which is an equity infusion intended to strengthen the balance sheet and capital structure. - The Rights Issue is part of a calibrated capital allocation framework to support growth. - As of the discussion, no specific details on the use of funds from the Rights Issue have been disclosed; specifics will be shared after the Board meeting. - The company's net debt position is comfortable, with net debt to EBITDA ratio below 1.5x, indicating capacity to manage growth capex from existing cash flows and debt. - No explicit mention of new debt fundraising in the transcript; focus is on equity infusion via the Rights Issue.

- Expected capex for current year (FY '26) is about INR 275 crore - INR 280 crore. - Capex for next year (FY '27) is expected to be 10% - 12% higher than FY '26. - Planned addition of about 1,000 beds over the next 3-4 years, increasing from around 2,500-2,600 beds to about 3,500 beds. - Two upcoming greenfield projects in Bangalore (North Bangalore with 120+ beds and Whitefield), expected operational by end of FY '27. - Addition of about 20 beds by reconfiguring specs of the existing Centre of Excellence in Bangalore. - Brownfield expansion planned across major centers in Ahmedabad, Bangalore, Cuttack, Mumbai, and other cities. - Equity infusion via rights issue to strengthen balance sheet and capital structure; specifics to be shared post Board meeting.

- Expected sales growth is 15%+ annually, with aspirations to exceed this target. - Growth drivers: approximately 10% from volume growth and about 5% from Average Revenue per Patient (ARPP) growth. - Existing facilities currently operate at ~60% revenue potential, indicating significant headroom for growth. - Incremental bed additions of around 1,000 beds planned over the next 3-4 years, boosting capacity from ~2,200 to ~3,200+ beds. - Volume growth of about 8%-10% expected in key markets like Vizag and Bangalore. - New facilities launching include North Bangalore (120+ beds) by end of FY '27 and Whitefield in Bangalore. - Brownfield expansion (adding beds in existing centers) ongoing across multiple cities, with 20-60 beds per center. - About 80% of margin growth expected from existing centers, 10-12% from brownfield, and 5-6% from greenfield projects.

- The company expects sales growth of 15%+, with about 10% coming from volume growth and 5% from ARPP growth (Page 16). - EBITDA margin is projected to rise, with mature centers already delivering 25%-26% EBITDA margins and close to 30% ROCE; broad company margin aspirations are 23%-24% in 3-4 years (Pages 13 and 8). - Adjusted EBITDA for Q3FY26 was INR 111 crore, up 20% YoY; margins expanded to 17.5% from 16.5% (Page 3). - Revenue growth in 9M FY26 stood at 16% YoY with adjusted EBITDA growth of 20%, indicating strong earnings momentum (Page 6). - ROCE is currently 13.3% (pre-tax) with expectations to improve to about 20% over the next 4-5 years due to operational leverage and capex optimization (Pages 13 and 6). - Capex is expected at around INR 275-280 crore this year with 10%-12% higher in FY27 (Page 16). - The company maintains a conservative 15%+ growth guidance, though actual growth potential with new bed additions and existing capacity is higher (Page 7).

The provided transcript and document do not mention any details about the current or expected order book or pending orders for Healthcare Global Enterprises Limited. The focus of the discussion is primarily on financial performance, growth plans, bed capacity expansion, sales growth drivers (ARPP and volume), capex guidance, and operational metrics. There is no reference to order books or pending orders in the Q3 & 9M FY26 earnings call transcript or associated documents.